Davies Benjamin M, Smith James, Rikabi Sarah, Wartolowska Karolina, Morrey Mark, French Anna, MacLaren Robert, Williams David, Bure Kim, Pinedo-Villanueva Rafael, Mathur Anthony, Birchall Martin, Snyder Evan, Atala Anthony, Reeve Brock, Brindley David
Division of Trauma and Orthopaedic Surgery, Department of Surgery, University of Cambridge, Cambridge, UK.
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
J Tissue Eng. 2017 Aug 11;8:2041731417724413. doi: 10.1177/2041731417724413. eCollection 2017 Jan-Dec.
Cellular therapies, such as stem cell-based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to this more widespread adoption. An anonymous online questionnaire was developed, based on the findings of a pilot study. This was distributed to an audience of clinicians, researchers and commercial experts in 13 countries. The results were analysed for all respondents, and also sub-grouped by geographical region, and by profession of respondents. The results of the study showed that the most significant barrier was manufacturing, with other factors such as efficacy, regulation and cost-effectiveness being identified by the different groups. This study further demonstrates the need for these important issues to be addressed during the development of cellular therapies to enable more widespread adoption of these treatments.
细胞疗法，如基于干细胞的治疗方法，已得到广泛研究，并且开发出了众多产品和治疗手段。尽管如此，这些技术在医疗保健领域的应用相对有限。本研究旨在调查阻碍这些技术更广泛应用的因素。基于一项初步研究的结果，设计了一份匿名在线问卷。该问卷分发给了13个国家的临床医生、研究人员和商业专家。对所有受访者的结果进行了分析，并按地理区域和受访者职业进行了分组。研究结果表明，最主要的障碍是生产制造，不同群体还指出了其他因素，如疗效、监管和成本效益。这项研究进一步表明，在细胞疗法的开发过程中需要解决这些重要问题，以使这些治疗方法能够更广泛地应用。
